The human body has developed various mechanisms, through which it can protect itself against newly-developing cancer cells.
Although the cause of Parkinson's disease remains a mystery, scientists now have a better understanding of the earliest stages of abnormal aggregation of a key disease-associated protein.
An analysis by Mount Sinai researchers of over eight years of dietary data from more than 400,000 people has found that the relationship between high consumption of fruits and vegetables and a reduced risk of cancer is not as strong as commonly thought.
In September 2009, news stories reported that researchers in Canada had found an increased risk of pandemic H1N1 influenza in people who had previously been vaccinated against seasonal influenza.
Rush University Medical Center is leading a nationwide Phase 3 clinical trial to determine whether a promising vaccine for advanced melanoma can effectively treat the deadly skin cancer.
A federal appellate court has upheld a lower court ruling dismissing the first product liability lawsuit among thousands alleging British drugmaker AstraZeneca PLC's antipsychotic drug Seroquel triggered a patient's diabetes.
The Food and Drug Administration has approved a new version of the painkiller OxyContin designed to be harder for patients to abuse, but one of the regulator's doctors said it may offer only "an incremental advantage."
Allon Therapeutics' lead neuroprotective drug candidate, davunetide, has been granted Fast Track status from the FDA for the treatment of Progressive Supranuclear Palsy.
Olympus has unveiled its BX3 line of upright clinical and research microscopes with exclusive ergonomic and imaging features that provide unprecedented comfort, ease of use and accuracy.
The Automation Partnership (TAP), a leader in the design and development of innovative automation for life science applications, is pleased to announce its new advanced micro bioreactor system (ambr).
While several recent high-profile Hollywood celebrity cases have brought the problem to public attention, the rates of unintentional poisoning deaths have been on the rise for more than 15 years.
A recent study has found that using the contrast agent Indocyanine Green to label human embryonic stem cell-derived cardiomyocytes substantially improved efforts to optically track stem cells after transplanting them into heart tissues.
With the addition of big pharma and government laboratories to the community, the company has brought on board Andrea Barry as senior director of business development to drive this growing commercial initiative.
BioAlliance Pharma SA announced an exclusive partnership agreement with Therabel Group for the European commercialization rights of Loramyc and Setofilm.